Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer

Keyphrases

• Metastatic Castration-resistant Prostate Cancer (mCRPC) 100%
• Major Metabolites 100%
• Enzalutamide 100%
• Real-life Cohort 100%
• Exposure-response Assessment 100%
• Plasma Concentration 53%
• Prostate-specific Antigen 46%
• N-desmethyl Enzalutamide 33%
• Progression-free Survival 20%
• Non-responders 20%
• Carboxylic Acids 20%
• Antigen-independent 20%
• Adverse Events 13%
• Treatment Response 13%
• PSA Progression 13%
• Netherlands 6%
• Clinically Significant 6%
• Therapeutic Drug Monitoring 6%
• Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) 6%
• Pharmacokinetic Study 6%
• Active Metabolite 6%
• Non-associated 6%
• Multivariate Analysis 6%
• Univariate Analysis 6%
• Amsterdam 6%
• Clinical Endpoints 6%
• Everyday Practices 6%
• Dose Reduction 6%
• Steady State 6%
• Exposure-response 6%
• Outpatient Clinic 6%
• Antiandrogen 6%
• Prostate-specific Antigen Response 6%
• Tertiary Cancer Center 6%
• Prostate-specific Antigen Level 6%
• Treatment Interruption 6%
• Oral Agents 6%

Pharmacology, Toxicology and Pharmaceutical Science

• Castration Resistant Prostate Cancer 100%
• Enzalutamide 100%
• Prostate Specific Antigen 45%
• Progression Free Survival 15%
• Survival Time 15%
• Carboxylate 15%
• Adverse Event 10%
• Malignant Neoplasm 5%
• Therapeutic Drug Monitoring 5%
• Active Metabolite 5%
• Antiandrogen 5%
• Pharmacokinetics 5%